8-Cl TIBO is compared with the corresponding structure containing wild-type HIV-1 RT, the overall conformations of Tyr181Cys and wild-type HIV-1 RT and of the 8-Cl TIBO inhibitors are very similar. Some positional changes in the polypeptide backbone of the b6-b10-b9 sheet containing residue 181 are observed when the Tyr181Cys and wild-type complexes are compared, particularly near residue Val179 of b9. In the p51 subunit, the Cys181 side-chain is oriented in a similar direction to the Tyr181 side-chain in the wild-type complex. However, the electron density corresponding to the sulfur of the Cys181 side-chain in the p66 subunit is very weak, indicating that the thiol group is disordered, presumably because there is no significant interaction with either 8-Cl TIBO or nearby amino acid residues. In the mutant complex, there are slight rearrangements of the side-chains of other amino acid residues in the NNIBP and of the flexible dimethylallyl group of 8-Cl TIBO; these conformational changes could potentially compensate for the interactions that were lost when the relatively large tyrosine at position 181 was replaced by a less bulky cysteine residue. In the corresponding wild-type complex, Tyr181 in the p66 subunit has significant interactions with the bound inhibitor and the position of the Tyr181 side-chain is well defined in both subunits. Apparently the Tyr181:Cys mutation eliminates favorable contacts of the aromatic ring of the tyrosine and the bound inhibitor, reducing the stability of NNRTI binding. This is consistent with
Introduction
The rate of replication of human immunodeficiency virus type 1 (HIV-1) in infected patients is high; billions of new virus particles are produced every day (Ho et al., 1995; Wei et al., 1995) . Reverse transcriptase (RT) is responsible for copying the single-stranded viral RNA genome into doublestranded DNA, which is subsequently integrated into host cell chromosomes by the viral enzyme integrase. RT is an important target for drug therapy, not only because it is essential for viral replication but it also contains multiple sites where drugs can bind.
Two major classes of HIV-1 RT inhibitors have been developed. The nucleoside RT inhibitors (NRTIs) have been widely used to treat AIDS patients (for reviews, see Larder, 1993; Schinazi, 1993; De Clercq, 1995a,b) . However, many of these drugs are relatively toxic, which, coupled with the emergence of drug-resistant viral variants, has limited the therapeutic efficacy of the NRTIs (for reviews, see Schinazi, 1993; Tantillo et al., 1994; De Clercq, 1994 , 1995a . The other class of HIV-1 RT inhibitors are the non-nucleosides (NNRTIs) which are highly specific for HIV-1 RT (for reviews, see Young, 1993; De Clercq, 1995a,b; Arnold et al., 1996) . The NNRTIs are much less toxic than the NRTIs; nonetheless, the emergence of drug-resistant viral strains has limited the therapeutic efficacy of NNRTIs. The available structural and biochemical data make it clear that, although the NNRTIs are chemically diverse, they all bind at a common site in HIV-1 RT. However, the binding affinities and inhibitory activities of NNRTIs vary significantly, even among different derivatives in a single family. Mutations that engender resistance to NNRTIs cluster around the NNRTI binding pocket (NNIBP). Although many HIV-1 RT NNRTI-resistant variants show some degree of cross-resistance to several NNRTIs, individual inhibitors engender a particular and characteristic spectrum of resistance mutations. These variations could be due to differences in the specific interactions between a particular inhibitor and the amino acid residues that make up the NNIBP.
R86183, an 8-chloro TIBO derivative (8-Cl TIBO, tivirapine), and R82913, a 9-chloro TIBO derivative (9-Cl TIBO), are two members of the TIBO family of NNRTIs (Figure 1 ). 8-Cl TIBO has a selectivity index (ratio of cytotoxic to inhibitory concentrations) of about 30,000 and inhibits HIV-1 RT in MT-4 cells with an IC 50 value of 4.6 nM . The selectivity index for 8-Cl TIBO is about ten times higher than that for the unsubstituted prototype TIBO derivative R82150 and is comparable to that for AZT. With a selectivity index of 1000 and an IC 50 value of 33 nM, 9-Cl TIBO is relatively less potent and somewhat more toxic than 8-Cl TIBO. The cytotoxicity CC 50 value for 8-Cl TIBO is 140 mM and the CC 50 value for 9-Cl TIBO is 34 mM. Various biochemical and clinical studies (Larder, 1992; Balzarini et al., 1993a,b; Byrnes et al., 1993; Boyer et al., 1994; Pauwels et al., 1994; Vandamme et al., 1994) have shown that mutations conferring resistance to TIBO compounds include Leu100 : Ile, Lys103 : Asn, Val106 : Ala, Glu138 : Lys, Val179 : Asp, Tyr181 : Cys/Ile, and Tyr188 : His/Leu. Changes of amino acid residues in the NNIBP region of HIV-1 RT have differential effects on inhibition by 8-Cl TIBO and 9-Cl TIBO. For example, HIV-1 RT mutants containing Tyr181 : Cys and Val179 : Asp mutations in p66, and Glu138 : Lys in p51 are differentially sensitive to these two TIBO derivatives . The Tyr181 : Cys mutant (Tyr181Cys) of HIV-1 RT is frequently selected in the presence of NNRTIs, and is quite resistant to most NNRTIs including 9-Cl TIBO, but is relatively susceptible to inhibition by 8-Cl TIBO (the IC 50 value for this mutant is 130 nM; Pauwels et al., 1994) . For nevirapine (Byrnes et al., 1993; Richman et al., 1994) and a-APA (R89439; Pauwels et al., 1993) the IC 50 values for the Tyr181Cys HIV-1 RT mutant are 22.7 mM (0113-fold higher than for wild-type HIV-1 RT) and 5.9 mM (01000-fold higher than for a wild-type HIV-1 RT), respectively.
It has been proposed that losing favorable interactions between the aromatic ring of Tyr181 and bound NNRTIs is responsible for NNRTI resistance in the Tyr181Cys HIV-1 RT variant (Sardana et al., 1992; Nanni et al., 1993; Tantillo et al., 1994) . Recent kinetic studies of the Tyr181Cys HIV-1 RT enzyme (Spence et al., 1996) , alone and in complex with nevirapine, have suggested that the mutation primarily affects inhibitor binding. Nevirapine was found to dissociate faster from the Tyr181Cys mutant HIV-1 RT complex than from a complex with wild-type HIV-1 RT. Both biochemical studies and the ease with which the variant is selected suggest that the polymerization efficiency of the Tyr181Cys mutant HIV-1 RT is not significantly impaired compared to wild-type HIV-1 RT (Spence et al., 1996) .
Knowledge of the structures of a complex of Tyr181Cys HIV-1 RT with 8-Cl TIBO and of complexes of 8-Cl TIBO and 9-Cl TIBO with wild-type HIV-1 RT, which have been crystallized using similar conditions and in the same crystal form, should permit a direct comparison of these closely related structures. This paper reports the crystal structures of wild-type HIV-1 RT in complexes with both 8-Cl TIBO and 9-Cl TIBO at 3.0 Å resolution, and the crystal structure of Tyr181Cys mutant HIV-1 RT in complex with 8-Cl TIBO at 3.2 Å resolution. Prior to these structure determinations, the X-ray crystal structures of a number of HIV-1 RT/NNRTI complexes (Kohlstaedt et al., 1992; Ding et al., 1995b; Ren et al., 1995a ) and a complex of HIV-1 RT/DNA/Fab were reported. Ren et al. (1995b) reported an independent structure determination of 9-Cl TIBO complexed with HIV-1 RT in a different crystal form (this structure is discussed in a later section). Structures of unliganded HIV-1 RT have also been determined in a number of distinct crystal forms (Esnouf et al., 1995; Rodgers et al., 1995; Hsiou et al., 1996; E. Arnold et al., unpublished results) .
Results and Discussion
Structure of the NNIBP in complexes of HIV-1 RT with TIBO and other NNRTIs HIV-1 RT is a heterodimer consisting of two polypeptide chains, p66 and p51. The p51 subunit has the same sequence as the 440 N-terminal amino acid residues of p66. This constitutes the polymerase domain. The p66 subunit also contains RNase H, which p51 lacks. In the HIV-1 RT/TIBO complex crystals, an asymmetric unit contains one p66/p51 heterodimer and one inhibitor molecule. The folding of the polymerase domains of p66 and p51 into fingers, palm, thumb, and connection subdomains is similar to that reported for the other HIV-1 RT structures.
As in other HIV-1 RT/NNRTI structures, the TIBO inhibitors are located in the NNIBP and adopt a ''butterfly-like'' conformation (Ding et al., 1995a; Ren et al., 1995a) . In this analogy, the dimethylallyl group of TIBO, or wing I of the butterfly (Ding et al., 1995a) , interacts with amino acid residues Pro95, Tyr181, Tyr188, Gly190, and Trp229 of p66, and the benzodiazepinone group of TIBO (wing II) interacts with Lys101, Lys103, Val106, Phe227, His235, Pro236, and Tyr318 of p66 (Figures 1 and 2 ). Residues Leu100 and Leu234 of p66 interact with both wings I and II from the top, Val179 from the front, and Tyr188 from the back (or the tail) of the butterfly (Figure 2(a) ). The amino acid residues surrounding the bound inhibitor are mostly hydrophobic; five contain aromatic side-chains. The only amino acid residues around the NNIBP that have charged side-chains (Lys101 and Lys103 of p66 and Glu138 of p51) are located near the putative entrance to the binding pocket (Ding et al., 1995b) . In the following discussion, residues that are mentioned without any chain identification are in the p66 subunit.
In contrast to TIBO derivatives, the other NNRTIs whose structures have been determined in complex with HIV-1 RT (Kohlstaedt et al., 1992; Ding et al., 1995b; Ren et al., 1995a) contain two distinct aromatic rings corresponding to the two wings in the butterfly analogy (Ding et al., 1995a) . In those structures, the wing I aromatic ring has extensive hydrophobic contacts with the surrounding amino acid residues; wing II has relatively fewer interactions with the surrounding amino acids. In the HIV-1 RT complexes with a-APA (Ding et al., 1995b; Ren et al., 1995a) , nevirapine The wings I and II portions of the inhibitors in the butterfly-like analogy for NNRTIs (Ding et al., 1995a) (Carson, 1987) . (a) Structures of the NNIBP regions of the HIV-1 RT/8-Cl TIBO complex (backbone colored dark red) and the HIV-1 RT/9-Cl TIBO complex (backbone colored light purple) which have been superposed based on all 985 C a atoms. The 8-Cl TIBO inhibitor is colored green and 9-Cl TIBO is gold. The chlorine atoms are shown in magenta. Side-chains of amino acid residues with close contacts to the bound inhibitors are displayed for the HIV-1 RT/8-Cl TIBO complex (cyan) and for the HIV-1 RT/9-Cl TIBO complex (light purple). (b) Structures of the NNIBP regions in the wild-type HIV-1 RT/8-Cl TIBO complex (backbone in dark red) and in the Tyr181Cys HIV-1 RT/8-Cl TIBO complex (gray) which were superposed based on all C a atoms. The 8-Cl TIBO inhibitor is colored green in the wild-type complex and is gold in the mutant complex. Side-chains of amino acid residues with close contacts to the bound inhibitors are displayed for the wild-type HIV-1 RT/8-Cl TIBO complex (cyan) and for the Tyr181Cys HIV-1 RT/8-Cl TIBO complex (gray). The perimeter of the base of the cone depicts the possible loci of the sulfur atom (S g ) of the disordered Cys181 side-chain in the mutant complex. (Smerdon et al., 1994; Ren et al., 1995a) , and HEPT (Ren et al., 1995a; Hopkins et al., 1996) , Tyr181 and Tyr188 have aromatic-aromatic ring interactions with wing I of the bound inhibitors, albeit the extent of interaction varies considerably among these complexes. Substitutions of non-aromatic amino acids at positions 181 and 188 lead to resistance to most NNRTIs both in cell culture and in clinical trials (for example, see Nunberg et al., 1991; Richman et al., 1991; Balzarini et al., 1993a; Byrnes et al., 1993; Richman, 1993) . Site-directed mutagenesis indicated that HIV-1 RT variants lacking aromatic amino acids at positions 181 and 188 display a significantly reduced sensitivity to a number of NNRTIs, including TIBO derivatives (Sardana et al., 1992) . It was surprising to find, in the structures of HIV-1 RT/TIBO complexes, that the aromatic benzodiazepine ring of the bound TIBO inhibitors occupies the wing II position, whereas the dimethylallyl group is located at the wing I position. Consequently, TIBO compounds have relatively few close contacts with the aromatic rings of Tyr181 and Tyr188 (Figure 1(a) and (c)). As can be seen in Figure 2 (a), the dimethylallyl group of TIBO is nearly perpendicular to the indole plane of Trp229 and is flanked by the Tyr181 and Tyr188 rings. The methyl groups of the dimethylallyl moiety of TIBO have a number of interactions with the side-chain of Trp229 (Figure 1 ). So far, none of the mutations reported to cause NNRTI resistance involve Trp229.
Binding of individual TIBO inhibitors to wild-type HIV-1 RT
Both 8-Cl TIBO and 9-Cl TIBO bind to HIV-1 RT in a similar, butterfly-like, fashion (Figure 2 ), but the specific interactions of the bound TIBO inhibitors with the protein and the precise geometry of the NNIBP are different. Superposition of all 985 C a atoms in the p66/p51 heterodimers in the respective structures showed a root-meansquared (RMS) deviation of 0.86 Å . On the basis of this superposition, the two bound TIBO inhibitors also superimpose very well, with the maximum separation between equivalent pairs of atoms being about 0.4 Å . The chlorine substituents, which are at different positions on the two drugs, are separated by 3.1 Å in the superposed complexes (Figure 2(a) ). Most of the interactions between the protein and wing I of the TIBO inhibitors are conserved in both structures (Figure 1(a) and (c)). The conformations of the amino acid residues surrounding wing I are quite similar in the two complexes. The major differences in the protein structure are around wing II of TIBO, in particular near the chlorine atoms. In the HIV-1 RT/8-Cl TIBO complex structure the chlorine atom is positioned near the tail of the butterfly. The closest contacts with the 8-Cl atom are 3.8 Å with the C d2 atom of Phe227 and 4.1 Å with the C b atom of Leu234. The chlorine atom in the 9-Cl TIBO/HIV-1 RT complex is positioned toward the outer edge of wing II and points towards the b13-b14 turn with nearest-neighbor atoms C d2 of Phe227 (at a distance of 4.0 Å ), C b of Leu234 (3.3 Å ), N and O of His235 (3.7 Å and 3.4 Å ), and O h of Tyr318 (3.2 Å ). There is an expansion of the NNIBP near the b13-b14 turn (residues 235 to 238) in the 9-Cl TIBO complex relative to the 8-Cl complex. The C a atom of Pro236 is displaced 1.5 Å relative to the position of the corresponding atom in the HIV-1 RT/8-Cl TIBO structure ( Figure 3 ). Hopkins et al. (1996) have shown that the position of this structural segment varies considerably in different HIV-1 RT/NNRTI complex structures. If the 9-Cl TIBO inhibitor is modeled into the NNIBP of the HIV-1 RT/8-Cl TIBO structure, the distances between the 9-chlorine atom of the inhibitor and the N and O atoms of His235 would be 3.0 Å and 2.8 Å , respectively. These distances are slightly shorter than are normally observed for non-bonded interactions involving these atoms. The converse experiment did not show any unfavorable short contacts for a atoms of the amino acid residues of structural elements aE, aF, b6, and b10 (which form the core of the palm subdomain) were used as the basis for superposition. The RMS deviation in this region between the wild-type and the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO complexes is 0.3 Å and the RMS deviation between the wild-type HIV-1 RT complexes with 8-Cl TIBO and 9-Cl TIBO is 0.5 Å .
8-Cl TIBO in the binding pocket of the HIV-1 RT/9-Cl TIBO complex. The solvent-accessible volumes of the NNIBP, calculated using VOIDOO (Kleywegt & Jones, 1994a ) and a solvent probe radius of 1.4 Å , were quite similar (9-Cl TIBO, 133 Å 3 and 8-Cl TIBO, 129 Å 3 ). However, visualization of the cavity volumes using the program O (Jones et al., 1991) indicated that the NNIBP cavity in the 9-Cl TIBO complex is extended towards Ser105, Pro225, Phe227, His235, and Pro236. The distance between the b5-b6 connecting loop and the b13-b14 hairpin, which are in the vicinity of the chlorine substituent of 9-Cl TIBO, is increased relative to the 8-Cl structure. This may be due to repositioning of the nearby NNIBP residues to avoid steric conflicts with the chlorine atom. An HIV-1 RT variant containing the mutation Pro236 : Leu was found to have increased sensitivity to 9-Cl TIBO (Dueweke et al., 1993) , suggesting that this substitution might favorably enhance interactions between the protein and the inhibitor, which is consistent with the proximity of this residue to the TIBO compound. In the HIV-1 RT/8-Cl TIBO structure, the interactions of Tyr318 with the surrounding protein atoms are different from those in the HIV-1 RT/9-Cl TIBO structure. In the 8-Cl TIBO complex, the O h atom of Tyr318 is 2.5 Å from the carbonyl oxygen of His235 (C-O . . . O angle of 104°) and may form a hydrogen bond. The distance between the Tyr318 O h atom and the chlorine atom of 8-Cl TIBO is 5.6 Å . In the HIV-1 RT/9-Cl TIBO structure, the displacement of the b13-b14 hairpin causes the carbonyl oxygen atom of His235 to be 3.3 Å away from the Tyr318 O h atom (C-O . . . O angle of 87°). The Tyr318 O h atom is relatively close (3.2 Å ) to the chlorine atom of 9-Cl TIBO. Superposition of the two structures also reveals that the b5-b6 connecting loop in the region near Lys103 has different positions in the two complexes, with the separation of Lys103 C a atoms being 1.0 Å ( Figure  3) . The potential hydrogen bond interaction between N1 of TIBO and the carbonyl oxygen atom of Lys101 is apparently weaker in the 9-Cl TIBO complex structure (with an N . . . O distance of 3.0 Å ) than in the 8-Cl TIBO complex structure (with an N . . . O distance of 2.6 Å ). The b12 strand near Phe227 and Leu228 in the 9-Cl TIBO complex is also moved outward from the pocket by about 1.5 Å relative to its position in the 8-Cl TIBO complex (Figures 2(a) and 3) . These conformational differences are indicative of the flexibility of the NNIBP, which can adopt shapes that are complementary to different bound inhibitors (Smith et al., 1995) .
Binding of 8-Cl TIBO to Tyr181Cys mutant HIV-1 RT
The folding of the polypeptide chains in the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO complex is similar to that of the wild-type HIV-1 RT/8-Cl TIBO complex (Figure 2(b) ). The RMS deviation is 0.54 Å for all 985 C a atoms. This high degree of similarity indicates that the Tyr181 : Cys mutation causes only minor changes in the global conformation of HIV-1 RT. This is consistent with biochemical data (Spence et al., 1996) showing almost identical polymerization activities for wildtype HIV-1 RT and the Tyr181Cys mutant. In the mutant complex the position and the side-chain orientation of Cys181 in the p51 subunit is well defined. The S g atom of this residue points in a similar direction (x 1 = −154°) to the side-chain of Tyr181 of p51 (x 1 = −175°) in the corresponding complex with wild-type HIV-1 RT. However, the replacement of tyrosine at position 181 by cysteine in the p66 subunit has both structural and functional consequences. In the p66 subunit of the mutant HIV-1 RT/8-Cl TIBO complex, the mainchain conformation of amino acid residue 181 appears to be relatively unperturbed by the Tyr181 : Cys mutation. However, there is a notable difference in the disposition of the side-chains of amino acid residue 181 in p66 between the two complexes. In the 8-Cl TIBO complex with wild-type HIV-1 RT and those of other wild-type HIV-1 RT/NNRTI complexes, the Tyr181 side-chain is well defined and is positioned such that it points away from the NNIBP and towards the polymerase active site. Substitution of Tyr181 by cysteine replaces the large aromatic side-chain with a thiol (SH) group. No clear electron density was observed (in maps calculated at various stages of structure determination and using various weighting schemes; see Materials and Methods) that could be assigned reliably to the S g atom of Cys181 of p66. This is in contrast to the well-ordered electron density observed for Cys181 of p51. Calculations which assume that the side-chain of Cys181 in p66 adopts one of the three ideal rotamers of a cysteine side-chain predict that the S g atom of Cys181 would have a short contact with an atom of 8-Cl TIBO with a distance of 2.4 Å for one rotamer (x 1 = 60°), but no short contacts for the other two rotamers (x 1 = 180°and x 1 = 300°). However, a minor adjustment of x 1 away from 60°w ould permit adoption of this rotamer without causing steric interference with the bound inhibitor. None of the three preferred rotamers of the Cys181 side-chain would lead to steric interference with other protein atoms. The electron density maps (even at lower contour levels) do not indicate a preference for any of the rotamers of the Cys181 side-chain in p66, indicating that the thiol group of the Cys181 side-chain in p66 is flexible and may adopt multiple positions in the complex with 8-Cl TIBO. The S g of Cys181 in p51 makes contacts with the nearby Pro97 residue (with an S g -C d distance of 3.4 Å ; and an S g -C g distance of 3.5 Å ); these interactions potentially account for the relatively stable position of S g in Cys181 in p51. The position of the inhibitor, 8-Cl TIBO, is essentially the same in the mutant and wild-type HIV-1 RT complexes. For example, the hydrogen bond between the N1 atom of 8-Cl TIBO and the (Jones et al., 1991) and VOIDOO (Kleywegt & Jones, 1994a ) with a solvent probe radius of 1.4 Å .
carbonyl O atom of Lys101 is almost unaffected by the Tyr181 : Cys mutation (Figure 1) . However, the torsion angles around the C5-N6-C12-C13 and N6-C12-C13-C14 bonds of the dimethylallyl group of 8-Cl TIBO are different in the wild-type (111°and 153°) and mutant HIV-1 RT (121°and 164°) structures. The side-chain of Tyr188 of p66 in the mutant HIV-1 RT/8-Cl TIBO complex also has slightly different torsion angles (x 1 = −79°, x 2 = 66°) from those of Tyr188 in the wild-type HIV-1 RT/8-Cl TIBO complex (x 1 = −77°, x 2 = 55°). Small changes in the torsion angles of both the dimethylallyl group of 8-Cl TIBO and the sidechain of Tyr188 combine to yield increased interactions between the dimethylallyl group of the inhibitor and the Tyr188 side-chain in the mutant complex (Figure 1(a) and (b) ). Additionally, the positions of Val179 are somewhat different in the mutant and wild-type HIV-1 RT/8-Cl TIBO complexes. Superposition of the two structures indicates that the C a atom of Val179 in the mutant HIV-1 RT/8-Cl TIBO complex is further away from the bound inhibitor by 0.8 Å compared to its position in the wild-type HIV-1 RT/8-Cl TIBO complex (Figures 1(a) , (b), 2(b), and 3). As a consequence, the interaction between Val179 and the bound TIBO inhibitor is weaker in the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO structure (Figure 1) .
Pocket volume calculations (Figure 4) show that the NNIBP in the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO complex is substantially larger than that in the wild-type HIV-1 RT/8-Cl TIBO complex (160 Å 3 versus 129 Å 3 ), assuming the disordered Cys181 side-chain of p66 in the mutant structure has the same x 1 side-chain torsion angle as that of Tyr181 of p66 in the wild-type HIV-1 RT/8-Cl TIBO structure (x 1 = −176°). The expansion of the NNIBP in the mutant HIV-1 RT/8-Cl TIBO complex occurs in the region around amino acid residues 179 and 181 (Figures 2(b) and 4) .
Possible mechanism of drug resistance caused by the Tyr181 : Cys mutation
Residue Tyr181 forms an integral part of the NNIBP in complexes of wild-type HIV-1 RT and NNRTIs; the extent of its interaction with the inhibitor depends on which inhibitor is bound. Since the Tyr181Cys HIV-1 RT variant is quite resistant to many NNRTIs, it is reasonable to expect significant differences in the shape, volume, and chemical character of the NNIBP in the Tyr181Cys mutant HIV-1 RT. The disorder of the side-chain of Cys181 in p66 in the Tyr181Cys HIV-1 RT/8-Cl TIBO structure suggests that the hydrophobic interactions of the side-chain of amino acid residue 181 with the bound NNRTI and side-chains of surrounding amino acid residues are lost when the tyrosine present at this position in wild-type HIV-1 RT is replaced by cysteine. This significant change in the NNIBP may be responsible for reduced affinity of Tyr181Cys HIV-1 RT for 8-Cl TIBO and other NNRTIs. On the other hand, in the Tyr181Cys HIV-1 RT complex with 8-Cl TIBO, Tyr188 shows relatively more interactions with the bound inhibitor compared to the corresponding wild-type complex. The loss of interactions of 8-Cl TIBO with amino acid residue 181 in the Tyr181Cys mutant could be compensated to some extent by increased interactions with the Tyr188 side-chain. This might partly explain why 8-Cl TIBO is still a relatively potent inhibitor of Tyr181Cys HIV-1 RT.
Numerous studies have indicated that the Tyr181 : Cys HIV-1 RT mutant, in general, is more resistant to nevirapine and a-APA derivatives than to TIBO derivatives (Byrnes et al., 1993; Pauwels et al., 1993 Pauwels et al., , 1994 Richman et al., 1994) . Structures of HIV-1 RT complexes with nevirapine (Smerdon et al., 1994; Ren et al., 1995a ) and a-APA (Ding et al., 1995b; Ren et al., 1995a) have shown that these compounds have more extensive interactions with Tyr181 than do TIBO compounds (Ding et al., 1995a; Ren et al., 1995b) . This could explain why these and numerous other NNRTI compounds are relatively inefficient in inhibiting HIV-1 RT carrying the Tyr181 : Cys mutation. It seems likely that the Tyr181 : Cys mutation has more profound effects on the binding of NNRTIs which interact extensively with Tyr181 in the wild-type HIV-1 RT/NNRTI complex. However, considering that Tyr181 is also positioned at the putative entrance to the NNIBP, as seen in HIV-1 RT structures in the absence of an NNRTI, we cannot rule out the possibility that the Tyr181 : Cys mutation could also affect entry into or egress from the pocket.
The flexibility of the torsion angles orienting the dimethylallyl moiety of 8-Cl TIBO permits the inhibitor to have more interactions with Tyr188 in the Tyr181Cys mutant complex; this conformational flexibility could also explain why 8-Cl TIBO is still relatively potent in inhibiting this mutant. One suggestion for inhibitor design that emerges from these considerations is that flexibility of the wing I portion of NNRTIs may be useful for increasing potency against several key NNRTI-resistant HIV-1 RT variants, including the Tyr181Cys mutant.
Displacement of the primer grip by NNRTIs could explain the kinetic data
Comparison of the HIV-1 RT/TIBO complex structures with other NNRTI-bound HIV-1 RT structures (Smerdon et al., 1994; Ding et al., 1995b) , unliganded HIV-1 RT (Rodgers et al., 1995; Hsiou et al., 1996) , and the HIV-1 RT/DNA/Fab complex structure indicates that the b6-b10-b9 sheet is a relatively stable structural element whose gross conformation and position changes little upon NNRTI binding. However, the b12-b13-b14 sheet has relatively greater flexibility and undergoes large conformational and positional changes (>4 Å movements) upon inhibitor binding.
Various mechanisms of inhibition by NNRTIs have been proposed on the basis of structural and biochemical data (Kohlstaedt et al., 1992; Tantillo et al., 1994; Ding et al., 1995b; Esnouf et al., 1995; Rittinger et al., 1995; Rodgers et al., 1995; Smith et al., 1995; Spence et al., 1995; Hsiou et al., 1996 . For a review, see Sarafianos et al., 1996) . Detailed biochemical and kinetic studies of HIV-1 RT inhibition by TIBO and other NNRTIs have indicated that NNRTIs do not prevent dNTP binding but instead reduce the rate of the chemical step of DNA polymerization (Rittinger et al., 1995; Spence et al., 1995) . Comparison of the HIV-1 RT/TIBO structures with the HIV-1 RT/DNA/Fab structure (Jacobo-Molina et al., 1993) reveals a large shift in the positions of the b12-b13-b14 sheet ( Figure 5 ). In the unliganded HIV-1 RT structures (Rodgers et al., 1995; Hsiou et al., 1996) this b-sheet occupies a position similar to that found in the HIV-1 RT/DNA/Fab structure. Hence, the displacement of the b12-b13-b14 sheet relative to the rest of the palm subdomain seems to be a consistent consequence of NNRTI binding. Since the b12-b13-b14 sheet (which contains the primer grip) interacts with the 3'-terminal phosphate of the primer strand, movement of this sheet is likely to affect the position and/or mobility of the primer terminus and consequently the position of the 3'-OH group which is the site of attachment of the incoming nucleotide (Tantillo et al., 1994; Ding et al., 1995b; Rodgers et al., 1995; Smith et al., 1995; Hsiou et al., 1996) . It is reasonable to expect that modification of the position or mobility of the 3'-OH by NNRTI binding would interfere with the chemical step of DNA polymerization, which is consistent with biochemical observations (Rittinger et al., 1995; Spence et al., 1995) . Alternatively, comparison of the structures of the HIV-1 RT/DNA/Fab and HIV-1 RT/NNRTI complexes reveals significant conformational differences of the YMDD motif (part of the b6-b10-b9 sheet) at the catalytic site (as reflected by displacements of C a positions of 2 Å or more; (Ding et al., 1995b) . Even though these positional changes are smaller in magnitude than those of the primer grip, they involve the catalytically essential Asp185 and Asp186 at the active site, and thus could potentially impair the chemical step of polymerization. A serious limitation of the available information is that none of the NNRTI-bound HIV-1 RT structures contain either template-primer of dNTP. The various mechanisms of NNRTI inhibition that have been proposed need not be mutually exclusive. Further structural studies of HIV-1 RT complexed with both NNRTIs and nucleic acid substrates should help to resolve some of the remaining questions.
Materials and Methods

Crystallization and diffraction data collection
Samples of HIV-1 RT were prepared and purified using methods described (Arnold et al., 1992; Jacobo-Molina et al., 1993; Clark et al., 1995) . Samples of the Tyr181Cys mutant HIV-1 RT were prepared and purified in a manner similar to wild-type HIV-1 RT, except that all buffers contained 5 mM DTT. However, the final Tyr181Cys HIV-1 RT preparations were aliquoted and stored at −70°C at a concentration of 16 mg/ml (due to extensive losses of the mutant enzyme during the purification and concentration procedures) rather than at 40 mg/ml as for wild-type HIV-1 RT preparations. Wild-type HIV-1 RT complexes with 8-Cl TIBO and 9-Cl TIBO were crystallized using conditions (Clark et al., 1995) modified from those described earlier by Kohlstaedt et al. (1992) for crystallization of HIV-1 RT complexed with nevirapine. Initial attempts at co-crystallization of HIV-1 RT with 8-Cl TIBO yielded small crystals. Larger crystals of wild-type HIV-1 RT/8-Cl TIBO were grown by streak seeding (Stura & Wilson, 1990 ) of three-day-old equilibrated hanging drops, using micro seeds obtained from crushing small HIV-1 RT/8-Cl TIBO crystals. Crystals of wild-type HIV-1 RT/9-Cl TIBO were grown without seeding. The typical size for these crystals was about 1.0 mm × 0.5 mm × 0.2 mm. Crystals of the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO complex grew much more slowly than wild-type HIV-1 RT/TIBO crystals; the maximum size of the mutant complex crystals was only about 0.2 mm × 0.2 mm × 0.05 mm, sufficient for data collection using flash freezing techniques (Teng, 1990; Rodgers, 1994) . All crystals were grown at 4°C.
Crystals of wild-type HIV-1 RT with 8-Cl TIBO and 9-Cl TIBO and the Tyr181Cys mutant HIV-1 RT complex with 8-Cl TIBO all crystallized in space group C2 with similar unit cell parameters (Table 1) , which were within a few percent of the values for the structures of the HIV-1 RT/nevirapine (Kohlstaedt et al., 1992) and HIV-1 RT/a-APA (Ding et al., 1995b) complexes. Shrinkage of the unit cell dimensions by approximately 1% was consistently observed when comparing the unit cells in frozen (−165°C) versus cooled (−10°C) crystals. Changes in structure between the frozen and cooled crystal forms do not correspond to a uniform shrinkage, but rather to subtle rearrangements of the structure. Thus, even these relatively minor differences in cell parameters permitted effective application of the multiple crystal form averaging procedure for phase improvement (see below).
In the crystal structure determination of the HIV-1 RT/TIBO complexes, six different X-ray diffraction datasets were used (Table 1) . To freeze crystals, the wild-type HIV-1 RT/TIBO crystals were soaked in 20 ml solutions of synthetic mother liquor (50 mM bis-Trispropane (pH 6.8), 100 mM (NH4)2SO4, and 12% (w/v) polyethylene glycol 8000) containing 1 ml of TIBO stock solution (10 mM TIBO in dimethyl sulfoxide and 5% (v/v) b-octylglucoside) and 17%, 23%, and 30% (v/v) glycerol, respectively, in time steps of approximately 30 minutes each. The soaked crystals were directly frozen in the liquid N2-cooled gaseous stream (−165°C). However, this stepwise soaking protocol did not work for crystals of the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO complex. These crystals were found to be very sensitive to the cryoprotectant solutions described above. Crystals of the Tyr181Cys HIV-1 RT/8-Cl TIBO complex were successfully frozen by quickly dipping a crystal into 20 ml of synthetic mother liquor (see above) containing 1 ml of TIBO stock solution and 30% (v/v) glycerol and then transferring directly to the liquid N2-cooled gaseous stream. All diffraction datasets were processed with DENZO (Minor, 1993; Otwinowski, 1993) and scaled with either SCALEPACK (Otwinowski, 1993) or SCALA (Evans, 1993) of the CCP4 suite (Collaborative Computational Project, 1994) . Datasets from the cooled wild-type HIV-1 RT/8-Cl TIBO complex crystals and from a frozen wild-type HIV-1 RT/9-Cl TIBO complex crystal (Table 1) were relatively more complete, and the structures of wild-type HIV-1 RT/TIBO complexes discussed in this paper have been refined using these datasets.
Structure determination and refinement
The structure of the wild-type HIV-1 RT/8-Cl TIBO complex was determined using the molecular replacement technique as implemented in X-PLOR 3.1 (Brü nger, 1993) and coordinates of the HIV-1 RT/a-APA complex as a starting search model against the cooled diffraction data. In order to improve the phase quality and reduce model bias, at the earlier stages of structure determination the electron density maps from the HIV-1 RT/8-Cl TIBO, HIV-1 RT/a-APA, and HIV-1 RT/BHAP complexes were averaged at 3.0 Å resolution (Ding et al., 1995b) using the multiple crystal form averaging routines in RAVE (Kleywegt & Jones, 1994b) combined with programs from the CCP4 package (Collaborative Computational Project, 1994). Model building based on the averaged maps using the program O (Jones et al., 1991) and positional refinement were carried out. The protein model from the cooled crystal structure was placed in the frozen crystal unit cell by applying translations of 2.8 Å and 1.4 Å along the x and z directions, respectively, that were determined from a translation search in Patterson space. In the later stages of structure determination, electron density maps calculated with the cooled (−10°C) and frozen crystal (−165°C) datasets were averaged using multiple crystal form averaging.
In order to further reduce model bias, omit maps were calculated and used in the multiple electron density map averaging. In omit map calculations, the asymmetric unit was divided into ten sections with each section containing an approximately equal number of atoms. The omit map for an individual section was calculated using the phase information from the partial model consisting of the remaining nine sections. In an attempt to reduce the ''memory'' of the omitted atoms, the partial model was refined for three cycles using PROLSQ (Hendrickson, 1985) and the phases computed from the resulting model were used to calculate the omit map for the omitted section. Then the ten omit maps calculated for all ten individual sections were merged together to complete one asymmetric unit which was then extended to cover the entire molecule.
In general, the averaged electron density maps were of superior quality (Figure 6 (a) and showed improved electron density in many regions of the protein. In the final stages of model building and refinement, the electron density map averaging was performed using program Dmmulti (Cowtan, 1994) . The model building of the protein, prior to inclusion of the inhibitor, was guided using both the individual and averaged omit maps.
Both the difference Fourier map (Fobs − Fcalc) (Figure 6(b) ) and the averaged electron density map (Figure 6(a) ) computed for the HIV-1 RT/8-Cl TIBO complex clearly indicated the position of the bound inhibitor. Both electron density maps were calculated using phases derived from only the protein model, before any structural information about the bound inhibitor was included either in structure refinements or in the map calculations. Initial coordinates for the TIBO model were obtained from small-molecule crystal structures (Liaw et al., 1991) . The small-molecule crystal structure of 9-Cl TIBO showed two possible conformations (designated as A and B) that vary in the configuration of the seven-membered diazepine ring. In both conformations the benzimidazole ring is nearly planar. Conformation A has its seven-membered ring in the TS configuration (Boessenkool & Boeyens, 1980) . The dimethylallyl (or methylbutenyl) side group is above the mean plane with C12 (C15 in the small molecule crystal structure numbering scheme) in an axial position. However, in the B conformation the seven-membered ring has the TC/BS configuration with C12 in an equatorial position (Liaw et al., 1991) . Both of these conformations could be accommodated in the electron density with minor modifications of a few torsion angles. A major difference in fitting the two possible conformations of TIBO in the NNIBP corresponds to the orientation of the aromatic ring system. In order to determine the position of the chlorine atom of TIBO in the NNIBP, a difference Fourier map (Figure 6(b) ) was calculated between the datasets for the HIV-1 RT/8-I TIBO (R89076) and the HIV-1 RT/8-Cl TIBO complexes at 4.5 Å resolution. This map unambiguously identified the correct position for the halogen atom and consequently resolved the potential ambiguity in the overall orientation of TIBO in the NNIBP. The information from the difference Fourier map computed between the iodinated and chlorinated TIBO derivatives, together with the asymmetric shape of the electron density for the inhibitor, permitted us to select the B conformation of TIBO as a starting model. The fit of the B conformation of TIBO into the omit electron density was optimized by a small change in the torsion angle around the N6-C12 bond that permitted the methyl carbon atoms of the dimethylallyl group to fit the electron density well (Figure 6(b) ).
Structure refinement of the wild-type HIV-1 RT/8-Cl TIBO complex yielded an R value of 24.9% using 24,961 reflections and a free R value (Brü nger, 1992) of 35.6% using 1288 reflections with Fobse2s(Fobs) in the resolution range between 10.0 Å and 3.0 Å for the cooled dataset (Table 1) . Individual isotropic thermal parameters were refined (Bar = 39 Å 2 ). The final model contains 7833 non-hydrogen protein atoms and 21 TIBO atoms. Due to weak electron density for the side-chains, amino acid Figure 6 . Electron density maps used in the structure determination of wild-type HIV-1 RT complexes with 8-Cl and 9-Cl TIBO (drawn using program O (Jones et al., 1991) . (a) Stereoview of a portion of an averaged (2wFobs − Fcalc) omit map (calculated using SIGMAA weights (Read, 1986) ; contour level 1.2s, magenta) at 3.2 Å resolution in the NNIBP region of the HIV-1 RT/8-Cl TIBO complex structure. The map was averaged between diffraction datasets measured from frozen and cooled crystals of the HIV-1 RT/8-Cl TIBO complex using programs RAVE (Kleywegt & Jones, 1994) and the CCP4 package (Collaborative Computational Project, 1994) . (b) A 3.0 Å resolution difference Fourier (Fobs − Fcalc) electron density map (contour level 2s, cyan) for 8-Cl TIBO in the HIV-1 RT/8-Cl TIBO complex calculated before the inhibitor was included in structure refinement and map calculation, and the difference Fourier map (contour level 4s, magenta) computed between the HIV-1 RT/8-I TIBO complex and the HIV-1 RT/ 8-Cl TIBO complex at 4.5 Å resolution, showing the location of the halogen atom. (c) A 3.0 Å resolution difference Fourier (Fobs − Fcalc) electron density map (contour level 2s, cyan) for 9-Cl TIBO in the HIV-1 RT/9-Cl TIBO complex. Again, the map was calculated before any information about the bound 9-Cl TIBO inhibitor was incorporated in structure refinement and map calculation. Electron density (calculated using 2Fobs − Fcalc coefficients; contour level 1.2s, magenta) for portions of the Tyr181Cys HIV-1 RT mutant complex with HIV-1 RT at 3.2 Å resolution. (a) In the p66 subunit, there is no ordered electron density for the side-chain sulfur atom of Cys181 (residue highlighted in green with an arbitrary position of S g shown), indicating disorder of the thiol group. In contrast, the 8-Cl TIBO inhibitor has well-ordered electron density. (b) In the p51 subunit, the electron density for the Cys181 side-chain is well defined.
residues 36, 66, 71, 72, 134 to 139, 218 to 223, 249, 281 to 293, 297 to 302, 311, 312, 323, 356 to 358, 366, 451, and 556 to 558 in p66 and 13, 121, 197, 199, 220, 222 to 230, 270, 278, 281, 357, 358 , and 361 to 363 in p51 were modeled as alanine residues. The portions corresponding to residues 65 to 72 and 134 to 139 in p66 and 222 to 230 in p51 have poorly defined electron density that did not permit reliable modeling in those regions.
The crystal structure of the wild-type HIV-1 RT/9-Cl TIBO complex was determined starting with the protein model of the HIV-1 RT/8-Cl TIBO structure. The averaged omit maps corresponding to the HIV-1 RT/9-Cl TIBO structures in the frozen and cooled crystals were calculated in a similar fashion to that described for the HIV-1 RT/8-Cl TIBO complex. The electron density for the inhibitor (Figure 6(c) ), obtained before including the inhibitor in the structure refinement and map calculations, was adequate to define the position and orientation of the TIBO inhibitor in the binding pocket. The statistics of the structure refinement and the final model are listed in Table 1 . In the final model, amino acid residues 36, 66, 71, 72, 134, 135, 139, 218 to 223, 249, 281 to 293, 297 to 302, 311, 312, 323, 356 to 358, 366, 451, and 556 to 558 in p66 and 13, 121, 197, 199, 220, 222 to 230, 270, 278, 281, 357, 358 , and 361 to 363 in p51 were modeled as alanine residues.
The crystal structure of the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO complex was determined starting with the model of the wild-type HIV-1 RT/8-Cl TIBO complex with the exclusion of the inhibitor and the side-chains of the amino acid residue 181 in both p66 and p51 subunits. The difference Fourier maps and the omit maps calculated using the scheme described earlier showed clear electron density for the bound inhibitor that allowed us to define the position and orientation of 8-Cl TIBO without any ambiguity (Figure 7(a) ). The electron density was well defined for the side-chain of Cys181 in the p51 subunit (Figure 7(b) ). However, no clear electron density was observed for the side-chain of Cys181 in the p66 subunit (Figure 7(a) ), suggesting that the side-chain of Cys181 in p66 is disordered. The statistics of the structure refinement and the final model are listed in Table 1 . In the final model, the following amino acid residues were modeled as alanines: 36, 66, 71, 72, 134 to 139, 218 to 223, 249, 281 to 293, 297 to 302, 311, 312, 323, 356 to 358, 366, 451, and 556 to 558 in p66 and 13, 121, 197, 199, 220, 222 to 230, 270, 278, 281, 357, 358 , and 361 to 363 in p51.
Comments on the conformation of TIBO bound to HIV-1 RT
A structure determination of the HIV-1 RT/9-Cl TIBO complex at 2.6 Å resolution in a different crystal form (P2 1 2121) has been reported (Ren et al., 1995b) . Though this paper confirmed that 9-Cl TIBO bound to HIV-1 RT in the same overall mode as we had described for the HIV-1 RT/8-Cl TIBO complex (Ding et al., 1995a) , it proposed that the conformation of the bound 9-Cl TIBO differed slightly from that which we reported for 8-Cl TIBO. In the structure of the HIV-1 RT/9-Cl TIBO complex reported by Ren et al. (1995b) , the conformation of the seven-membered ring and the chirality of the sp 3 -hybridized N6 atom appear to be different from what was reported for the small-molecule crystal structures (Liaw et al., 1991) and from what we have found for structures of 8-Cl TIBO (Ding et al., 1995a) and 9-Cl TIBO in complexes with HIV-1 RT (this paper). In the structure reported by Ren et al. (1995b) the seven-membered diazepine ring is nearly coplanar with the benzimidazole ring and the methyl group at the C5 position and the dimethylallyl group at the N6 position lie on either side of the mean plane of the three fused ring system. The coordinates for the HIV-1 RT/9-Cl TIBO complex structure reported by Ren et al. (1995b) are unavailable so we are unable to compare their structure directly with our structures. We built a model of 9-Cl TIBO with geometry similar to that shown in Figures 3 and 4 of Ren et al. (1995b) (hereafter referred to as conformation C to distinguish from the A and B conformations (Liaw et al., 1991) ). Omit difference Fourier maps (using either (Fobs − Fcalc) or (2Fobs − Fcalc) coefficients) were calculated prior to inclusion of the TIBO inhibitors in both the wild-type HIV-1 RT/ TIBO complexes and the fit of each of the three conformations (A, B, and C) was evaluated. The difference Fourier maps showed electron density that could be fit most consistently with the B conformation of TIBO. Experiments including the modeled C conformation of TIBO in electron density map calculations, followed by structure refinement, showed poor density for the dimethylallyl side group, suggesting that the C conformation of TIBO is not consistent with our experimental data. In our structure determination of the HIV-1 RT/8-Cl TIBO complex, the electron density for the methyl group attached at the C5 position was reasonable in the averaged omit maps (Figure 6a ). Although the electron density for this methyl group was not clear in the HIV-1 RT/9-Cl TIBO complex (Figure 6c ), all electron density maps showed clear density for the large dimethylallyl side group in both the HIV-1 RT/8-Cl TIBO and HIV-1 RT/9-Cl TIBO complexes. Since conformational changes of the seven-membered ring are coupled with the position of the dimethylallyl group of TIBO, the conformation of the dimethylallyl group of TIBO in the C conformation is not consistent with the electron density maps.
In the C conformation of TIBO, the dimethylallyl group and the methyl group, attached to N6 and C5, respectively, are in trans configuration and the dihedral angle of C11-C5-N6-C12 is approximately 140°. The corresponding torsion angles in the A and B forms of TIBO are 71°and −54°, respectively. In order to assess the observed distribution of this dihedral angle for available benzodiazepine derivative structures, we searched the Cambridge Crystallographic Data Bank for smallmolecule structures containing a benzodiazepine group (fused benzene and seven-membered rings). Out of 23 closely related benzodiazepine structures that have a chiral center at position 5 and a tetrahedral carbon at position 6, none has the two chemical groups/atoms attached at positions 5 and 6 in the trans configuration. The dihedral angle for C11-C5-N6-C12 or its equivalent in any of these structures is within 275°and the two chemical groups attached at positions 5 and 6 tend to lie on the same side of the mean plane of the benzodiazepine ring.
Taking all of these considerations into account, we believe that the orientation and conformation of TIBO inhibitors presented provide the best explanation of our experimental observations. With moderate resolution diffraction data, we have taken precautions to improve the quality of electron density and reduce model bias through multiple crystal form map averaging and omit maps. However, we do not rule out the possibility that the TIBO inhibitor might adopt other conformations in the HIV-1 RT/TIBO complex crystallized in different crystal forms such as that seen by Ren et al. (1995b) .
Data deposition
The full coordinates of the HIV-1 RT/8-Cl TIBO (R86183) complex (PDB entry 1HNV), the HIV-1 RT/9-Cl TIBO (R82913) complex (PDB entry 1TVR), and the Tyr181Cys mutant HIV-1 RT/8-Cl TIBO (R86183) complex (PDB entry 1UWB) have been deposited with the Brookhaven Protein Data Bank for immediate release.
